Emergent BioSolutions Inc. EBS R2KR3KPHARMA
Company Overview
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic botulism; BioThrax, an anthrax vaccine; CYFENDUS, a vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; Ebanga, a monoclonal antibody for the treatment of infection caused by Orthoebolavirus zairense; Raxibacumab injection, a monoclonal antibody therapeutic for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis; TEMBEXA, an oral antiviral for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; and CNJ-016, a polyclonal antibody therapeutic to address complications from smallpox vaccination. It also provides NARCAN and KLOXXADO nasal sprays for the emergency treatment of known or suspected opioid overdose. In addition, the company offers contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, analytical development, and suite reservation services. Emergent BioSolutions Inc. was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Why Investors Should Care
Operating margin of 28.4% supports profitability.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $742.90M (-28.8% YoY); net profit $52.60M.
- Trailing 12 Months Year-on-year growth — revenue +66.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 7.5%, profit CAGR 3.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 7.46% |
| 1 Year: | 66.30% |
Compounded Profit Growth
| 5 Years: | 3.33% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -29.35% |
| 6 Months: | -25.09% |
| 3 Months: | -23.05% |
| 1 Month: | +16.95% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)54.30 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Trading 55.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | EBS Emergent BioSolutions Inc. R2KR3KPHARMA | 6.21 | -1.82 | $318.41M | 0.00% | 8.44% | -40.29% | 7.46% | 3.33% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 116.90M | 100.80M | 149.40M | 193.80M | 117.80M | 220.20M | 173.70M | 270.70M | 190.60M | 243.20M | 311.80M | 360.40M | 192.50M | 394.70M | 385.20M | 583.00M | 343.00M | 397.50M | - | - | - | - | - | - | - | 300.40M | 254.70M | 293.80M | 222.20M | 140.90M | 231.10M | 156.10M | 234.30M |
| Gross Profit | 35.10M | 63.16M | 65.15M | 21.16M | -2.04M | 35.48M | 50.93M | 14.90M | 8.50M | 47.80M | 53.10M | -9.50M | 66.80M | 21.30M | 11.20M | -27.40M | -7.00M | 70.70M | 77.80M | - | - | - | - | 222.40M | 144.30M | 94.60M | 142.00M | 65.60M | 75.30M | 4.90M | 140.70M | 87.20M | 147.80M | -48.00M | 161.20M | - | - | - | - | - |
| Operating Income | 21.45M | 63.16M | 49.89M | 21.16M | -2.04M | 35.48M | - | 14.91M | 8.53M | 47.77M | - | -9.50M | 66.80M | 21.30M | - | -27.40M | -7.00M | 70.70M | 77.80M | -11.60M | 126.00M | 61.30M | 258.10M | 95.40M | 14.50M | -34.70M | 6.90M | -76.30M | -45.30M | -147.60M | -292.90M | -242.10M | 39.80M | -203.50M | 64.50M | 49.90M | 1.60M | 76.50M | 10.50M | -125.10M |
| Net Income | 14.10M | 36.94M | 33.35M | 3.99M | -10.95M | 21.34M | - | 10.48M | 4.62M | 33.55M | - | -4.90M | 50.10M | 20.90M | -3.40M | -26.10M | -9.50M | 43.20M | 46.90M | -12.50M | 92.70M | 39.50M | 185.40M | 69.70M | 4.60M | -32.70M | -4.60M | -52.90M | -87.10M | -186.20M | -261.40M | -263.40M | 9.00M | -283.10M | 114.80M | 68.00M | -12.00M | 51.20M | 6.80M | -180.20M |
| Diluted EPS | 0.32 | 0.79 | 0.71 | 0.10 | -0.27 | 0.45 | 0.77 | 0.23 | 0.11 | 0.68 | - | -0.10 | 0.98 | 0.41 | -0.07 | -0.51 | -0.18 | 0.83 | 0.90 | -0.24 | 1.73 | 0.73 | 3.44 | 1.28 | 0.09 | -0.61 | -0.09 | -1.06 | -1.75 | -3.71 | -5.16 | -5.08 | 0.17 | -5.38 | 2.06 | 1.19 | -0.22 | 0.91 | 0.07 | -3.49 |
| R&D Expense | 40.94M | 34.18M | - | 26.09M | 27.89M | 27.19M | - | 20.48M | 25.75M | 22.66M | - | 29.10M | 24.70M | 37.00M | - | 46.10M | 63.90M | 53.40M | - | 42.70M | 47.90M | 84.40M | - | 52.50M | 48.90M | 49.60M | 46.40M | 49.80M | 42.20M | 40.70M | 26.00M | 15.30M | 15.10M | 32.70M | 13.80M | 15.10M | 12.50M | 13.50M | 10.50M | 9.20M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 234.79M | 286.17M | 273.38M | 281.89M | 312.75M | 450.14M | 522.79M | 488.80M | 560.90M | 782.40M | 1.11B | 1.56B | 1.77B | 1.12B | 1.05B | 1.04B | 742.90M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | 916.30M | 891.30M | 383.00M | 317.60M | - | - |
| Operating Income | 40.15M | 73.56M | 32.10M | 29.97M | 42.80M | 89.19M | 141.51M | 105.50M | 124.30M | 89.80M | 114.10M | 433.80M | 341.40M | -170.00M | -726.40M | -108.70M | 100.10M |
| Net Income | 31.14M | 51.70M | 23.02M | 23.52M | 31.14M | 36.74M | 62.87M | 51.80M | 82.60M | 62.70M | 54.50M | 305.10M | 219.50M | -211.60M | -760.50M | -190.60M | 52.60M |
| Diluted EPS | 0.99 | 1.59 | 0.64 | 0.65 | 0.85 | 0.88 | 1.41 | 1.13 | 1.71 | 1.22 | 1.04 | 5.67 | 4.06 | -4.22 | -14.85 | -3.60 | 0.93 |
| R&D Expense | 74.59M | 89.30M | 124.83M | 120.23M | 119.93M | 104.72M | 119.19M | 106.90M | 97.40M | 142.80M | 226.20M | 234.50M | 235.20M | 188.30M | 111.40M | 70.70M | 53.20M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 500.32M | 546.86M | 564.23M | 626.63M | 938.69M | 1.04B | 970.11M | 1.07B | 2.23B | 2.33B | 2.88B | 2.96B | 3.17B | 1.82B | 1.39B | 1.32B |
| Total Equity | 199.35M | 243.81M | 369.46M | 414.25M | 441.36M | 489.62M | 553.20M | 660.00M | 596.20M | 912.30M | 1.01B | 1.09B | 1.45B | 1.61B | 1.39B | 649.30M | 482.80M | 522.60M |
| Cash & Equivalents | 91.47M | 102.92M | 169.02M | 143.90M | 141.67M | 179.34M | 280.50M | 312.80M | 271.50M | 178.30M | 112.20M | 167.80M | 621.30M | 576.10M | 642.60M | 111.70M | 99.50M | 205.40M |
| Long Term Debt | - | - | 30.24M | 54.09M | 58.30M | 62.00M | 251.00M | 246.89M | 248.09M | 13.50M | 784.50M | 798.40M | 841.00M | 809.40M | 448.50M | 446.50M | 663.70M | 572.10M |
| Total Liabilities | - | - | 126.76M | 130.14M | 122.10M | 137.47M | 385.49M | 377.47M | 373.91M | 157.90M | 1.22B | 1.24B | 1.44B | 1.34B | 1.78B | 1.17B | 906.90M | 796.00M |
| Current Liabilities | - | - | 75.72M | 71.05M | 61.91M | 56.65M | 92.94M | 99.61M | 105.86M | 100.10M | 200.40M | 216.30M | 384.50M | 373.80M | 1.23B | 651.30M | 162.40M | 132.20M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 29.87M | 98.02M | 12.19M | 39.64M | 96.97M | 112.32M | 42.52M | 54.60M | 208.10M | 41.80M | 188.00M | 536.00M | - | -34.10M | -206.30M | 58.70M | 170.60M |
| Investing Cash Flow | -33.29M | -23.46M | -53.96M | -40.11M | -67.89M | -210.05M | -45.46M | -76.20M | -249.90M | -897.20M | -96.90M | -151.00M | - | -381.30M | 212.30M | 125.20M | 69.40M |
| Financing Cash Flow | 14.84M | -8.45M | 16.66M | -1.76M | 8.61M | 198.87M | 35.39M | -19.80M | -51.40M | 788.70M | -35.90M | 69.50M | - | 481.20M | -535.70M | -190.00M | -136.60M |
| Capital Expenditure | -33.29M | -22.10M | -54.03M | -53.84M | -42.02M | -30.67M | -44.81M | -76.20M | -54.80M | -72.10M | -86.90M | -141.00M | - | -115.80M | -51.60M | -22.90M | -13.80M |
| Free Cash Flow | -3.42M | 75.92M | -41.84M | -14.20M | 54.95M | 81.64M | -2.29M | -21.60M | 153.30M | -30.30M | 101.10M | 395.00M | - | -149.90M | -257.90M | 35.80M | 156.80M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | 65.80M | -529.70M | -6.10M | 103.40M |
| Share Buybacks | - | 0 | 0 | 5.91M | 213.00K | 200.00K | 100.00K | 0 | 33.10M | 100.00K | 0 | 0 | 106.00M | 82.10M | 0 | 0 | 24.90M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | 58.9% | 50.3% | 34.3% | 30.3% | - | - |
| Operating Margin % | 17.1% | 25.7% | 11.7% | 10.6% | 13.7% | 19.8% | 27.1% | 21.6% | 22.2% | 11.5% | 10.3% | 27.9% | 19.2% | -15.2% | -69.2% | -10.4% | 13.5% |
| Net Margin % | 13.3% | 18.1% | 8.4% | 8.3% | 10.0% | 8.2% | 12.0% | 10.6% | 14.7% | 8.0% | 4.9% | 19.6% | 12.4% | -18.9% | -72.5% | -18.3% | 7.1% |
| ROE % | 12.8% | 14.0% | 5.6% | 5.3% | 6.4% | 6.6% | 9.5% | 8.7% | 9.1% | 6.2% | 5.0% | 21.0% | 13.6% | -15.2% | -117.1% | -39.5% | 10.1% |
| ROCE % | - | 17.3% | 6.7% | 6.0% | 7.5% | 10.5% | 15.1% | 12.2% | 12.8% | 4.4% | 5.4% | 17.4% | 13.2% | -8.8% | -62.0% | -8.9% | 8.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 9.20% | 4.72M | $27.88M |
| 2 | Dimensional Fund Advisors LP | 6.00% | 3.08M | $18.18M |
| 3 | State Street Corporation | 5.71% | 2.93M | $17.31M |
| 4 | American Century Companies Inc | 5.40% | 2.77M | $16.37M |
| 5 | Vanguard Capital Management LLC | 4.29% | 2.20M | $13.00M |
| 6 | LSV Asset Management | 3.31% | 1.70M | $10.02M |
| 7 | Acadian Asset Management. LLC | 2.62% | 1.34M | $7.94M |
| 8 | Geode Capital Management, LLC | 2.61% | 1.34M | $7.90M |
| 9 | Charles Schwab Investment Management, Inc. | 2.34% | 1.20M | $7.10M |
| 10 | Oak Hill Advisors, L.P. | 2.17% | 1.11M | $6.58M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for EBS
Emergent Biosolutions Stock Price Forecast. Should You Buy EBS? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiR0FVX3lxTE52YUROd2xWNTFTeDhzVUFrT2lVc0E3cXVRYnFWMlZVb1lLX21TRHh0cm55YmQyWjRaY2xXN1pVdXA2enRWcWhz?oc=5" target="_blank">Emergent Biosolutions Stock Price Forecast. Should You Buy EBS?</a>&nbs…
$EBS stock is down 8% today. Here's what we see in our data. - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxNXzFzNmNKOFNWTUNrckdsN3c4a3JCLUtBZ1h4OWJaNXBTcGM5WjNoaXVFZ3NlUlNiMmk5dkt2NndSXzJYNVlSbHFlcko5emtLVnZUX0JUb0lDOHEwbWxVQTRqU2k0M280NGtHLTFBd0l3aXZKR24zRDFCeHN2Vmx5eXNDaW9rN1VLYVdHOU…
Emergent BioSolutions: Tough 2026 Outlook Warrant Rating Downgrade (NYSE:EBS) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxNcHpZVU5xTTIwT01xNWthTU52d2tSd3Fuay1RR19kRWE4QXNvZTRPS2hFTEZ0RVJKWHhlMWlEN2oxOFdWeWJiSVJMSWVndTc4eUEwbEdmSG5aNC1QcjhmcXRIWGhXMXpDU2RmOFFTREZJRU5oN2pFcEdQSm5YWUFqQzBFQzB5VTJ1Y2tXam…
Emergent BioSolutions (EBS) Securities Investigation Notice - Levi & Korsinsky - PR Newswire
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxPcXNVNkVXcEhoOWM1eHpZZ2NHYWlKYm5GcG1MX3FidVZsdnNacVc1TGlNN3BqdWdidy1DTlRfYU5VZDB0ODNxbUJ6dEdLNUVHYTlWWEJjalZRbmI1TzJvZVYxUWNQMFg2bmdTX1FMRFFSRE5FaHpZd0dKOUNvTHNOU2NwaVppR1E1MzJ1az…
Emergent records $191.3M non-cash charge related to NARCAN asset group - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxOUGVUQXp5Qi1FSW9nbHNNWEQyclhncnpKR05iWlQwYmVwVU5Gd1RPQ3FDbVVMSTZ6OUxPc1lmOEpTUkZQWHZHdXA2MlcxMlFIMlRIelVVY3lUd1RPRnRnb25zSmhrQjMzamZZRlczek5JMkhvcF9BQ1Q0TUUwM2lBVVRvMXJrNnp2dGhiYm…
Discipline and Rules-Based Execution in EBS Response - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxOczR4elNyaVpHMnNGSVpuQTNQVDl4ZDRHa0hqUHJHTm5JQTlhYjY0LXl0NGNiNkVTT1ItckRrbVc0VWpzTjQtWmhfbDlyUXJDUkkxMk9reS1Sb3BrS2RqR2ZfYUR6cnhnNUNOVmpuM1BYV0xZSExsemZ0bzhWS1g5NWh2eDRtd3RxbGVyTE…
EBS — Frequently Asked Questions
What is the current share price of Emergent BioSolutions Inc. (EBS)?
As of 2026-09-07 16:24 PDT, Emergent BioSolutions Inc. (EBS) trades at $6.21 on NYSE. Its 52-week range is $4.45 to $13.90.
What is the market capitalisation of EBS?
Emergent BioSolutions Inc. (EBS) has a market capitalisation of $318.41M on NYSE.
What is the P/E ratio of EBS?
EBS trades at a trailing price-to-earnings (P/E) ratio of -1.82. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 0.48.
What is the return on equity (ROE) of EBS?
EBS has a return on equity (ROE) of -40.29%. Its return on capital employed (ROCE) is 8.44%.
Is EBS a good stock to buy?
This page provides a data-driven analysis of Emergent BioSolutions Inc. (EBS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.